Smith & Nephew to Acquire Osiris

Smith & Nephew (SNN) entered into an agreement to acquire Osiris Therapeutics for USD $19/share in cash, for a total equity value of ~$660MM.

While the transaction is largely complementary to SNN’s wound management business, Osiris also brings BIO4® viable bone matrix, an alternative to autograft, and Cartiform® cryopreserved viable...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us